Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulindac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.69 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 14/20 | 0.78 |
| ▸ | RXRA | P19793 | 6/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | EDNRA | P25101 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulindac SCHEMBL4203 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL30901384 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac Sulfoxide SCHEMBL755984 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL31324645 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL4202 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL29360981 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL6903607 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL30989491 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac Sulfoxide SCHEMBL11255653 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL15700834 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3687524-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | Medicon Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019067919-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20110159017-A1 | TRYTOPHAN CATABOLISM IN CANCER TREATMENT AND DIAGNOSIS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010008427-A1 | TRYPTOPHAN CATABOLISM IN CANCER TREATMENT AND DIAGNOSIS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-0805684-A4 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | UNIV TEXAS (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1998013073-A1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDs AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-04-02 | — | — | WO | disclosed |
| EP-0805684-A2 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022780-A1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-08-01 | — | — | WO | disclosed |
| US-4292319-A | MIXTURE WITH AN ANTIULCER AGENT | BOEHRINGER INGELHEIM GMBH (DE) | 1981-09-29 | — | — | US | disclosed |
| US-4256747-A | ANTIINFLAMMATORY AGENTS, PYRIDO/2,3B//1,4/BENZODIAZEPIN-6-ONES | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| US-4154833-A | INDOMETHACIN (1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOLE-3-ACETIC ACID) WITH PIRENZEPINE (5,11-DIHYDRO-11-((4-METHYL-1-PIPERAZINYL)-ACETYL)-6H-PYRIDO(2,3 -B)(1,4)BENZODIAZEPIN-6-ONE) | BOEHRINGER INGELHEIM GMBH (DE) | 1979-05-15 | — | — | US | disclosed |